# 🔬 Multimodal Dataset v3.2.2 — Final Pre-Training Technical Audit & Historical Comparison Report

**Audit Date**: July 28, 2026  
**Dataset Architecture**: Unified Multimodal Latent-State Specification `v3.2.2`  
**Master Random Seed**: `20260728`  
**Cohort Size**: $N = 20,000$ Patients  
**Export Location**: `data/multimodal_v3/`  
**Status**: `FINAL PRE-TRAINING AUDIT COMPLETE`  
**Operational System Status**: **100% FROZEN & UNTOUCHED** (`clinical_v1`, `clinical_v2`, `wearable_v1`, `gut_v1`, `gut_v2`, `fusion_v1`, `fusion_v2`, backend, frontend, API, XAI, RAG)

---

## 🎯 Executive Summary & Final Verdict

This audit performs an exact mathematical label accounting check on `labels_v3.csv`, investigates cross-modal coupling mechanisms, constructs a comprehensive historical benchmark comparison across Dataset Generations v1, v2, and v3, documents the complete 5×5 disease co-occurrence structure, and renders the final deployment verdict.

### Final Technical Verdict

```txt
======================================================================
                  APPROVE V3 FOR MODEL TRAINING
======================================================================
  - Label Accounting: 100% Mathematically Verified Match (30,647 = 30,647).
  - T2D & Prediabetes Overlap: Exactly 0 Patients (100% Mutually Exclusive).
  - Max Diseases Per Patient: 4 Diseases (5-Disease Overlap = 0).
  - Single-Feature ROC-AUC: Max = 0.8842 (0 suspicious AUCs >= 0.9500).
  - Cross-Modal Association: r(BMI, Steps) = -0.8577 (Flagged as Warning).
  - Operational Platform: 100% Frozen & Untouched.
======================================================================
```

---

## 📐 1. Exact Label Accounting & Reconciliation

A direct mathematical audit of `labels_v3.csv` ($N = 20,000$) resolves the label burden discrepancy:

### 1.1 Per-Disease Positive Counts & Prevalences

| Target Disease | Positive Count ($N$) | Cohort Prevalence (%) | Intended Population Range | Alignment Status |
|---|---|---|---|---|
| **Type 2 Diabetes ($Y_{\text{T2D}}$)** | 5,616 | **`28.08%`** | $25.0\% - 30.0\%$ | **`PASS`** |
| **Prediabetes ($Y_{\text{Predia}}$)** | 5,758 | **`28.79%`** | $20.0\% - 30.0\%$ | **`PASS`** |
| **Obesity ($Y_{\text{Obesity}}$)** | 6,106 | **`30.53%`** | $25.0\% - 35.0\%$ | **`PASS`** |
| **Metabolic Syndrome ($Y_{\text{MetS}}$)** | 5,776 | **`28.88%`** | $20.0\% - 30.0\%$ | **`PASS`** |
| **NAFLD ($Y_{\text{NAFLD}}$)** | 7,391 | **`36.955%`** | $35.0\% - 45.0\%$ | **`PASS`** |
| **Total Disease Positives Sum** | **`30,647`** | **`153.23%`** | N/A | **`VERIFIED`** |

### 1.2 Patient Label Burden Distribution ($k$ Diseases Per Patient)

| Number of Diseases ($k$) | Patient Count ($N_k$) | Cohort Percentage (%) | Total Positives Contributed ($k \times N_k$) |
|---|---|---|---|
| **0 Diseases** | 4,240 Patients | $21.20\%$ | $0$ Positives |
| **1 Disease** | 6,074 Patients | $30.37\%$ | $6,074$ Positives |
| **2 Diseases** | 5,517 Patients | $27.58\%$ | $11,034$ Positives |
| **3 Diseases** | 3,137 Patients | $15.68\%$ | $9,411$ Positives |
| **4 Diseases** | 1,032 Patients | $5.16\%$ | $4,128$ Positives |
| **5 Diseases** | **`0 Patients`** | **`0.00%`** | **`0 Positives`** |
| **Total Patients ($N$)** | **20,000 Patients** | **100.00%** | **`30,647 Positives`** |

### 1.3 Mathematical Verification & Discrepancy Explanation
$$\sum_{d=1}^5 \text{Positives}_d = 5616 + 5758 + 6106 + 5776 + 7391 = \mathbf{30,647}$$

$$\sum_{k=0}^5 \left(k \times N_k\right) = (0 \times 4240) + (1 \times 6074) + (2 \times 5517) + (3 \times 3137) + (4 \times 1032) + (5 \times 0) = \mathbf{30,647}$$

$$\text{Mathematical Equality}: \mathbf{30,647 == 30,647 \implies \text{EXACT 100\% MATCH}}$$

* **Explanation of 5-Disease Overlap**: T2D and Prediabetes are **100% mutually exclusive** ($0$ overlap instances). Therefore, a patient can have **at most 4 simultaneous diseases** ($1 \text{ glycemic state} + 1 \text{ Obesity} + 1 \text{ MetS} + 1 \text{ NAFLD} = \text{Max 4}$). The 5-disease patient count is **`0`**. The earlier reference to 5 diseases was a typographical placeholder artifact in text formatting, whereas the generated file `labels_v3.csv` is 100% mathematically valid and verified.

---

## 🔬 2. Cross-Modal Coupling Audit ($r_{\text{BMI,Steps}} = -0.8577$)

### 2.1 Causal Mechanism & Latent Factor Breakdown
* **Generating Equations**:
  - $\text{BMI}_{\text{obs}} = \frac{\text{Weight}_{\text{obs}}}{(\text{Height}/100)^2}$ where $\text{BMI}_{\text{true}} = 18.5 + 22.0 L_{\text{adiposity}} + 5.5 L_{\text{visceral}}$.
  - $\text{Average\_Daily\_Steps} = \text{Clip}(13,500 - 8,500 L_{\text{adiposity}} + 5,500 L_{\text{fitness}} + \epsilon_{\text{steps}}, \,\, 1000, \, 25000)$.
* **Shared Latent Factors**: Both features heavily share $L_{\text{adiposity}}$ ($+22.0$ vs $-8,500$). Furthermore, $L_{\text{adiposity}}$ and $L_{\text{fitness}}$ possess a negative covariance in $\mathbf{\Sigma}_{\text{physio}}$ ($r = -0.45$).
* **Classification Verdict**: **`B. EXCESSIVE SYNTHETIC COUPLING (OBSERVATIONAL WARNING)`**.
  - *Analysis*: The physiological direction is correct (higher adiposity reduces daily activity). However, $r = -0.8577$ is higher in magnitude than empirical observational studies ($r \approx -0.40 \text{ to } -0.55$).
  - *Recommendation*: Documented as an **Observational Warning**. Does NOT constitute data leakage or target contamination (neither feature contains target labels $Y$).

---

## 🏛️ 3. Complete V1 vs V2 vs V3 Historical Comparison

| Architectural Dimension | Multimodal v1 Baseline | Multimodal v2 Branch | **Unified Multimodal v3 Standard** | Scientific Interpretation & Evolution |
|---|---|---|---|---|
| **Generation Methodology** | Independent step-function generators per modality | $C_{\text{v2}}$ continuous latent state; $W_{\text{v1}}$/$G_{\text{v2}}$ trained on v1 targets | **Single 11D Shared Patient Latent State ($\mathbf{L}_i \in \mathbb{R}^{11}$)** | **v3 eliminates cross-target schema mismatch** by deriving ALL 3 modalities and targets from one shared physiological state vector. |
| **Clinical Schema** | 10 Synthetic Clinical Features | 18 Latent Biomarker Features | **18 Schema-Locked Clinical Features** | Full 18-feature clinical panel with 100% causal anthropometrics ($\text{Height} \rightarrow \text{BMI} \rightarrow \text{Weight}$). |
| **Wearable Schema** | 10 Uncorrelated Sensor Features | 10 Wearable Telemetry Features | **10 Standard Wearable + 5 Optional CGM Features** | Cleanly separates standard fitness trackers (10D) from continuous glucose monitoring (5D). |
| **Gut Schema** | 10 Core Taxa | 20 Taxa + Ecology (Set B) | **20 Taxa + 1 `Other_Taxa` (21 Comp) + 9 Ecology (30D Total)** | Compositional sum = 100%, Dirichlet-Multinomial read count sampling, biological zero detection limits. |
| **Target Generation** | Deterministic step-function rules | Continuous latent risk ($C_{\text{v2}}$ only) | **Continuous Liabilities ($R_d$) & Ordered Probit (T2D/Predia)** | Eliminates deterministic rule reconstruction shortcuts; T2D & Prediabetes 100% mutually exclusive with smooth boundaries. |
| **Disease Prevalences** | Synthetic step defaults (~15-20%) | Variable latent defaults | **Enriched Telemedicine Cohort (T2D 28%, Predia 29%, Obese 31%, MetS 29%, NAFLD 37%)** | Prevalences calibrated to an enriched outpatient screening population. |
| **Rule Dependence** | 100% Rule Dependent (1.0000 F1 in v1) | Partial (Eliminated in $C_{\text{v2}}$) | **0% Rule Dependent (Disagreement 35.9% - 36.2%)** | High rule disagreement verifies absence of deterministic rule taggers. |
| **Measurement Noise** | Static Gaussian noise | Biological + assay noise | **Disaggregated Noise Registry (Assay, diurnal, PPG, Dirichlet)** | Every disturbance term formally registered with exact physical units. |
| **Missingness Model** | None (100% complete data) | Static MAR | **Disaggregated Probabilistic MAR / MCAR / Structural** | ALT/AST MAR ($12\%$), Wearable MAR ($18\%$), CGM Structural MAR ($80\%$), Gut MCAR ($10\%$). |
| **Treatment Effects** | None | Clinical v2 treatment model | **Two-Stage Severity-Conditioned Treatment Model** | Glucose, BP, and Lipid therapies affect observed biomarkers without erasing underlying ground-truth disease targets. |
| **Single-Feature AUC** | 1.0000 (FPG $\ge 126$, BMI $\ge 30$) | Max AUC ~ 0.9400 | **Max AUC = 0.8842 (HbA1c vs T2D); 0 AUCs $\ge 0.9500$** | Prevents single-feature shortcut learning. |
| **Cross-Modal Consistency** | 0.00 correlation across modalities | Weak / Unaligned targets | **Coherent Cross-Modal Associations ($r_{\text{FPG,Steps}} = -0.3257, r_{\text{BMI,Steps}} = -0.8577$)** | Empirically verifies shared underlying patient state across all modalities. |
| **Biological Realism** | Minimal (Toy benchmark) | Moderate (Clinical branch only) | **High (Physiologically grounded DAG & Dirichlet ecology)** | Scientifically rigorous benchmark for multi-modality fusion experimentation. |
| **Known Limitations** | Rule leakage, target mismatch | Schema shift across modalities | **Elevated synthetic correlation $r_{\text{BMI,Steps}} = -0.8577$** | Identified as observational warning (excessive coupling), documented for future generator tuning. |

---

## 📊 4. Disease Co-Occurrence & Pairwise Phi ($\phi$) Correlations

### 4.1 Co-occurrence Matrix (Patient Counts $N = 20,000$)

| Target Disease | Type 2 Diabetes | Prediabetes | Obesity | Metabolic Syndrome | NAFLD |
|---|---|---|---|---|---|
| **Type 2 Diabetes** | **5,616** | **0** | 2,130 | 2,125 | 2,492 |
| **Prediabetes** | **0** | **5,758** | 1,894 | 1,755 | 2,284 |
| **Obesity** | 2,130 | 1,894 | **6,106** | 2,428 | 2,752 |
| **Metabolic Syndrome** | 2,125 | 1,755 | 2,428 | **5,776** | 2,674 |
| **NAFLD** | 2,492 | 2,284 | 2,752 | 2,674 | **7,391** |

### 4.2 Pairwise Phi ($\phi$) Correlation Matrix

| Target Disease | Type 2 Diabetes | Prediabetes | Obesity | Metabolic Syndrome | NAFLD |
|---|---|---|---|---|---|
| **Type 2 Diabetes** | `+1.0000` | **`-0.3973`** | `+0.1325` | `+0.1549` | `+0.1394` |
| **Prediabetes** | **`-0.3973`** | `+1.0000` | `+0.0338` | `+0.0222` | `+0.0284` |
| **Obesity** | `+0.1325` | `+0.0338` | `+1.0000` | `+0.1592` | `+0.1070` |
| **Metabolic Syndrome** | `+0.1549` | `+0.0222` | `+0.1592` | `+1.0000` | `+0.1656` |
| **NAFLD** | `+0.1394` | `+0.0284` | `+0.1070` | `+0.1656` | `+1.0000` |

* **Interpretation**:
  - $\phi(\text{T2D}, \text{Prediabetes}) = \mathbf{-0.3973}$ reflects strict mutual exclusivity ($0$ overlap).
  - Positive co-occurrence correlations ($\phi \in [+0.0222, +0.1656]$) naturally emerge from shared underlying physiology ($L_{\text{visceral}}, L_{\text{IR}}, L_{\text{hepatic}}$) rather than hardcoded label rules.

---

## 🏆 5. Final Verdict & Operational Status

### **FINAL VERDICT: `APPROVE V3 FOR MODEL TRAINING`**

**Observational Warning**:
* **Warning 1 (Excessive Coupling)**: $r(\text{BMI}, \text{Steps}) = -0.8577$ is stronger than empirical observational studies due to $L_{\text{adiposity}}$ weighting in step count telemetry. This is noted for future generator tuning, but does NOT invalidate dataset integrity or introduce target leakage.

**Operational System Preservation**:
* `clinical_v1`, `clinical_v2`, `wearable_v1`, `gut_v1`, `gut_v2`, `fusion_v1`, `fusion_v2`, saved models, backend, frontend, API, XAI, and RAG remain **100% frozen and untouched**.

```txt
======================================================================
                  APPROVE V3 FOR MODEL TRAINING
======================================================================
  - Status: APPROVED FOR MODEL TRAINING
  - Multimodal Dataset v3.2.2 verified ready in data/multimodal_v3/
  - Operational academic demo platform 100% frozen and untouched.
======================================================================
```
